Dr. Stuart Grant, Founder And Principal Consultant at Archetype MedTech, Tells TechRound About His Firm’s New “Expertise For Equity” Model
Archetype Medtech has introduced an "Expertise for Equity" model designed to assist early-stage medtech companies in bridging the gap between concept and commercialization. This model addresses a key challenge within the MedTech startup ecosystem:…
Archetype Medtech has introduced an "Expertise for Equity" model designed to assist early-stage medtech companies in bridging the gap between concept and commercialization. This model addresses a key challenge within the MedTech startup ecosystem: limited access to necessary expertise due to funding constraints.
Overview of the "Expertise for Equity" Model
The model allows Archetype Medtech to offer a comprehensive suite of services—covering innovation management, regulatory compliance, and design engineering—in exchange for equity. This approach aligns the firm's incentives with those of the founders, fostering a long-term partnership aimed at achieving commercial success.
LumipenPro™: This innovation integrates illumination, suction, and smoke evacuation into a tool for aesthetic surgery. Archetype Medtech has partnered with LumipenPro™ to obtain EU MDR approval and is now involved in enhancing the device's design for global scaling. C-True: C-True is advancing total shoulder arthroplasty with a portable, marker-less navigation system utilizing AI and augmented reality. Archetype Medtech is collaborating with C-True to refine the system for manufacturing and align it with regulatory requirements.
This model addresses a key challenge within the MedTech startup ecosystem: limited access to necessary expertise due to funding constraints.
The "Expertise for Equity" model mitigates the risk of "failure to launch" by ensuring that products are not only technologically advanced but also compliant with regulatory standards. Archetype Medtech conducts strategic reviews to optimize efficiency and enhance product viability.
MedTech entrepreneurs are advised to expedite their development timelines, as technological advancements can quickly render innovations obsolete. Successful navigation of regulatory and market entry challenges is crucial for ensuring that groundbreaking ideas reach patients.
Based on reporting by techround.co.uk.
